TCBPW Ebitda from 2010 to 2025

TCBPW Stock  USD 0.02  0  6.75%   
TC BioPharm EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -12.9 M in 2025. During the period from 2010 to 2025, TC BioPharm EBITDA regression line of quarterly data had mean square error of 4.3 T and geometric mean of  6,965,319. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-12.2 M
Current Value
-12.9 M
Quarterly Volatility
3.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TC BioPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TC BioPharm's main balance sheet or income statement drivers, such as Interest Income of 1.9 K, Depreciation And Amortization of 638 K or Interest Expense of 90.7 K, as well as many indicators such as Price To Sales Ratio of 0.5, Dividend Yield of 0.0 or PTB Ratio of 0.22. TCBPW financial statements analysis is a perfect complement when working with TC BioPharm Valuation or Volatility modules.
  
Check out the analysis of TC BioPharm Correlation against competitors.

Latest TC BioPharm's Ebitda Growth Pattern

Below is the plot of the Ebitda of TC BioPharm plc over the last few years. It is TC BioPharm's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TC BioPharm's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

TCBPW Ebitda Regression Statistics

Arithmetic Mean(7,432,451)
Geometric Mean6,965,319
Coefficient Of Variation(41.26)
Mean Deviation2,538,761
Median(5,714,170)
Standard Deviation3,066,889
Sample Variance9.4T
Range8.3M
R-Value(0.76)
Mean Square Error4.3T
R-Squared0.58
Significance0.0006
Slope(489,005)
Total Sum of Squares141.1T

TCBPW Ebitda History

2025-12.9 M
2024-12.2 M
2023-13.6 M
2022-11.3 M
2021-6.5 M
2020-5.3 M

About TC BioPharm Financial Statements

TC BioPharm investors use historical fundamental indicators, such as TC BioPharm's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TC BioPharm. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-12.2 M-12.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TCBPW Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.